Provides management advisory services to medical marijuana collectives. Licenses medical marijuana-related products for marketing and sale. Now — the numbers.
This is an established company with proven profits.
Average growth of 129% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $460K. In times of high interest rates, a gap like that can squeeze a company.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 32% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 9 years, sales grew about 129% a year on average.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.